GlassScriptPhysician profile
Samuel Abourbih
NPI 1518340280
$3,908.72
in general payments reported to CMS, 2019-2025
27 companies · $784 in 2025
The $784 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $618 · 2020: $209 · 2021: $612 · 2022: $410 · 2023: $746 · 2024: $529 · 2025: $784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,059.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,059.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $512.50 | 2019-2023 | Myrbetriq |
| Teleflex LLC | $428.44 | 2023-2025 | Barrigel, Urolift |
| Verathon INC. | $400.00 | 2021 | |
| Urogen Pharma, INC. | $380.62 | 2022-2023 | Jelmyto |
| Procept Biorobotics Corporation | $262.82 | 2023-2024 | Aquabeam Robotic System, Aquabeam System |
| Olympus America INC. | $254.94 | 2019-2025 | Itind System |
| Boston Scientific Corporation | $207.86 | 2019-2024 | Ams 700 |
| Sumitomo Pharma America, INC. | $196.77 | 2023-2025 | Gemtesa, Orgovyx |
| Progenics Pharmaceuticals, INC. | $187.40 | 2024-2025 | |
| Pfizer INC. | $155.13 | 2019-2025 | |
| Urovant Sciences INC | $134.07 | 2022 | |
| Endo Pharmaceuticals INC. | $127.21 | 2020-2022 | |
| Hollister Incorporated | $95.25 | 2020-2024 | Vapro Pocket |
| Tolmar, INC. | $71.49 | 2025 | Eligard, Jatenzo |
| Endo USA, INC. | $69.37 | 2025 | Xiaflex, Aveed |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abc Home Medical Supply, INC. | $68.37 | 2024-2025 | |
| Myriad Genetic Laboratories, INC. | $66.10 | 2024-2025 | Prolaris |
| Intuitive Surgical, INC. | $53.08 | 2019 | |
| Antares Pharma, INC. | $43.86 | 2021 | |
| Verona Pharma, INC. | $35.60 | 2025 | Ohtuvayre |
| Novartis Pharmaceuticals Corporation | $32.76 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.00 | 2023 | |
| Tempus Ai, INC | $22.83 | 2025 | Xt Cdx |
| Telix Pharmaceuticals | $21.56 | 2024 | Illuccix |
| Coloplast Corp | $20.77 | 2023 | Speedicath |
| Halozyme INC | $18.71 | 2023 | |
| Janssen Pharmaceuticals, INC | $16.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Abourbih listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.